

1 Stromal KITL/SCF promotes pancreas tissue homeostasis and restrains tumor progression

2

3 M. Kathrina Oñate^{1,2}, Chet Oon^{1,2}, Sohinee Bhattacharyya^{1,2}, Vivien Low¹, Canping Chen³,
4 Xiaofan Zhao³, Ziqiao Yan⁴, Yan Hang^{4,5}, Seung K. Kim^{4,5,6,7}, Zheng Xia³, Mara H. Sherman^{1,2,*}

5

6 ¹Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New
7 York

8 ²Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University,
9 Portland, Oregon

10 ³Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon

11 ⁴Department of Developmental Biology, Stanford University School of Medicine, Stanford,
12 California

13 ⁵Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford,
14 California

15 ⁶Department of Medicine, Stanford University School of Medicine, Stanford, California

16 ⁷Department of Pediatrics, Stanford University School of Medicine, Stanford, California

17

18 Running title: Mesenchymal KITL restrains pancreatic tumor growth

19

20 Keywords: tissue plasticity, pancreatic cancer, paracrine signaling, mesenchymal cells

21

22 *Corresponding author:

23 Mara H. Sherman, Ph.D.

24 Cancer Biology & Genetics Program

25 Memorial Sloan Kettering Cancer Center

26 417 E 68th Street Z-1261

27 New York, NY 10065

28 Tel: 646-888-3885

29 Email: shermam1@mskcc.org

30

31 Conflict of interest disclosure statement:

32 M.H. Sherman is a paid consultant for Autobahn Labs.

33 Word count: 3,330 words

34 Figure count: 4 main figures, 4 supplementary figures

35 **Abstract**

36

37 Components of normal tissue architecture serve as barriers to tumor progression. Inflammatory
38 and wound-healing programs are requisite features of solid tumorigenesis, wherein alterations to
39 immune and non-immune stromal elements enable loss of homeostasis during tumor evolution.
40 The precise mechanisms by which normal stromal cell states limit tissue plasticity and
41 tumorigenesis, and which are lost during tumor progression, remain largely unknown. Here we
42 show that healthy pancreatic mesenchyme expresses the paracrine signaling molecule KITL, also
43 known as stem cell factor, and identify loss of stromal KITL during tumorigenesis as tumor-
44 promoting. Genetic inhibition of mesenchymal KITL in the contexts of homeostasis, injury, and
45 cancer together indicate a role for KITL signaling in maintenance of pancreas tissue architecture,
46 such that loss of the stromal KITL pool increased tumor growth and reduced survival of tumor-
47 bearing mice. Together, these findings implicate loss of mesenchymal KITL as a mechanism for
48 establishing a tumor-permissive microenvironment.

49

50 **Statement of significance**

51

52 By analyzing transcriptional programs in healthy and tumor-associated pancreatic mesenchyme,
53 we find that a sub-population of mesenchymal cells in healthy pancreas tissue express the
54 paracrine signaling factor KITL. Loss of mesenchymal KITL is an accompanying and permissive
55 feature of pancreas tumor evolution, with potential implications for cancer interception.

56

57

58

59

60

61

62

63

64

65

66

67

68

69 **Main text**

70

71 **Introduction**

72

73 Though evidence that normal tissue components can restrain tumor progression dates back to
74 the 1960s (1), the specific tissue-level barriers to plasticity and tumor outgrowth remain largely
75 unknown. Mechanisms maintaining tissue homeostasis and limiting tumorigenesis include
76 epithelial-epithelial interactions, such as regenerative or competitive epithelial functions (2-4);
77 epithelial-immune interactions, wherein innate (5, 6) or adaptive (7, 8) immune cells clear mutant
78 cells or early pre-invasive lesions; and epithelial-mesenchymal interactions, with evidence that
79 mesenchymal elements such as normal tissue fibroblasts can restrain growth of transformed
80 epithelial cells (9-11). These mechanisms co-exist with, and likely interact functionally with,
81 epithelial cell-intrinsic tumor suppressor gene products, together creating genetic, cellular, and
82 tissue-level checks on cancer development. While epithelial cell-intrinsic mechanisms of tumor
83 suppression have been studied extensively, and we have advanced considerably in our
84 understanding of anti-tumor functions of the immune systems, mechanisms underlying the tumor-
85 restraining potential of normal mesenchyme largely have not been identified.

86

87 Fibro-inflammatory reactions create tissue contexts permissive to tumor progression (12, 13).
88 Local or systemic cues, including paracrine signaling from transformed epithelial cells or diverse
89 sources of tissue damage, cause alterations to resident mesenchymal cells such as transition
90 from quiescent fibroblasts to activated myofibroblasts and changes to or accumulation of immune
91 cells. This wound healing reaction helps to promote plasticity in the epithelial compartment and
92 overcome intrinsic barriers to tumor formation and growth (14). Consistent with this notion, though
93 normal primary fibroblasts can suppress hyperplastic growth of mammary epithelial cells *in vivo*,
94 this outgrowth is supported by activated, myofibroblastic stroma (15, 16). Though the causal link
95 between inflammation and cancer has been appreciated for some time (17), recent studies of
96 patient tissues have begun to identify specific mechanisms by which inflammatory insults promote
97 cancer development. For example, environmental pollutants result in an accumulation of IL-1 β -
98 producing macrophages in the lung, and this inflammatory signaling drives plasticity in the lung
99 epithelium to promote tumorigenesis (18). Further study of the specific signals engaged by healthy
100 or inflamed tissue components to restrain or promote tumorigenesis, respectively, may point to
101 new avenues for early cancer intervention.

102

103 The recent discovery that normal, adult human pancreas tissue harbors up to hundreds of *KRAS*-
104 mutant pre-invasive lesions impels the field to understand intracellular and heterocellular
105 mechanisms restraining neoplastic progression in the pancreas (19, 20). To assess a role for
106 mesenchymal cell state alterations in the transition from a homeostatic to tumor-permissive tissue
107 context, we performed transcriptional profiling of healthy and cancer-associated pancreatic
108 mesenchyme using an established fate mapping mouse model (21). These experiments focused
109 on pancreatic stellate cells (PSCs), tissue-resident mesenchymal cells which serve as cells of
110 origin for PDAC CAFs. We found that this mesenchymal lineage in normal human and murine
111 pancreas tissue expresses KITL—this lineage has lipid storage capacity and co-expresses the
112 leptin receptor (LEPR), with parallels to LEPR-positive mesenchyme previously implicated in
113 tissue homeostasis in the bone marrow (22) and brown adipose tissue (23). Mesenchymal KITL
114 expression is lost during tumor evolution and acquisition of a cancer-associated fibroblast (CAF)
115 stromal phenotype, with functional significance for tissue state and tumorigenic potential.

116

117 **Results**

118

119 To assess stromal evolution during stepwise tumorigenesis, we applied a previously established
120 fate mapping approach (21) to analyze the contributions PSCs to the stroma of normal pancreas
121 tissue, pancreatic intraepithelial neoplasia (PanINs), and invasive PDAC. To this end, we
122 generated a dual recombinase genetically engineered mouse model of the genotype *Kras*^{FSF-}
123 *G12D/+; Trp53*<sup>FRT/+; Pdx1-FloP; Rosa26^{cmTmG/+; Fabp4-Cre} (Figure 1A) and assessed the presence of
124 GFP⁺ stroma, indicating a lipid-storing origin. While GFP⁺ PSCs were found in normal pancreas
125 tissue as expected, very few were positive for PDPN, a cell surface marker upregulated upon
126 fibroblast activation in PDAC. We found GFP⁺PDPN⁺ cells associated with low-grade PanIN
127 lesions as well as invasive cancer in this model (Figure 1B & 1C), with a significant increase in
128 PSC-derived fibroblastic cells in the context of PDAC compared to pre-invasive lesions. In normal
129 pancreas tissue and in tumors, PSCs or PSC-derived CAFs had a spatial distribution similar to
130 the reported tissue distribution of stellate cells in the liver, the other tissue in the body where these
131 mesenchymal cells reside. Hepatic stellate cells (HSCs) are found in perivascular regions in close
132 proximity to endothelial cells, and adjacent to neighboring parenchymal cells (24). We found PSCs
133 in normal pancreas tissue similarly to localize in perivascular regions, and in the tissue
134 parenchyma spatially poised for cell-cell communication with epithelial cells (Figure 1D). This
135 spatial distribution was conserved upon differentiation to a CAF phenotype, as GFP⁺ CAFs were
136 found both immediately adjacent to and distant from endothelial cells in the genetically engineered</sup>

137 PDAC model (Figure 1E). Similar results were observed in an orthotopic model wherein PDAC
138 cells derived from the *Kras*^{LSL-G12D/+}; *Trp53*^{LSL-R172H/+}; *Pdx1-Cre* (KPC) autochthonous model were
139 implanted into syngeneic *Rosa26*^{cmTmG/+}; *Fabp4-Cre* hosts (Figure 1F). These observations indicate
140 that PSCs contribute to the stromal microenvironment throughout pancreatic tumorigenesis and
141 are spatially distributed to engage in direct cell-cell contact with both endothelial cells and
142 epithelial cells in healthy and cancerous pancreas tissue.

143

144 We next assessed alterations in expression of cell surface ligands or receptors in this
145 mesenchymal lineage during pancreatic tumorigenesis. We reasoned that paracrine signaling
146 factors important for normal tissue architecture may be lost from the mesenchyme during the
147 transition from normal tissue homeostasis to cancer. To identify candidate paracrine factors
148 associated with normal mesenchymal function whose loss may be tumor-permissive, we analyzed
149 the transcriptional profiles of PSCs and PSC-derived CAFs. To this end, we sorted GFP⁺ PSCs
150 and GFP⁺PDPN⁺ CAFs from healthy pancreas tissue and PDAC, respectively, and performed
151 single-cell RNA-seq (scRNA-seq) to assess gene expression differences in this cellular
152 compartment within and across tissue states. As expected, these cells in normal pancreas and
153 PDAC were pervasively positive for mesenchymal marker *Vim* and almost all positive for pan-
154 tissue fibroblast markers *Pi16* or *Col15a1* (25) (Figure 2A). Though not all cells expressed one of
155 these two universal fibroblast markers, we note that PSCs are not strictly fibroblasts albeit
156 fibroblast-like. While PSCs and PSC-derived CAFs are partially perivascular as described above,
157 these cells lacked expression of classical pericyte markers such as *Cspg4* (encoding NG2) and
158 *Rgs5* (Supplementary Figure S1A). Interestingly, the sub-population in normal pancreas tissue
159 lacking universal fibroblast markers expressed both *Vim* and genes generally associated with a
160 macrophage identity, such as *Csf1r* and *Adgre1* (encoding F4/80) (Supplementary Figure S1B).
161 However, when we stained for GFP and macrophages in pancreas tissues we detected no overlap
162 (Supplementary Figure S1C), suggesting that this sub-population of cells in normal pancreas
163 tissue may be fibrocyte-like or otherwise express some macrophage-associated genes without
164 assuming a macrophage identity. In the context of cancer, PSCs gained expression of immune-
165 modulatory cytokines such as *il6* and *Il33* as expected for CAFs (26) and pervasively expressed
166 extracellular matrix (ECM) components such as *Col1a2* (Figure 2B). These results validate
167 activation of PSCs to a CAF phenotype in PDAC.

168

169 We next focused on paracrine signaling factors expressed in healthy pancreatic mesenchyme
170 and lost in PDAC which may represent barriers to tumor progression. We noted expression of *Kitl*

171 (also known as stem cell factor or SCF) in normal pancreas tissue but lost in CAFs (Figure 2C),
172 supported by pseudo-time analysis (Supplementary Figure S2A). KITL expression has not
173 previously been reported in normal pancreas tissue, and was of interest to us in light of the
174 significance of KITL-positive mesenchyme in the perivascular niche of the bone marrow, where
175 stromal KITL is crucial for normal tissue structure and function (22). Further, HSCs in the
176 developing liver are critical sources of KITL to support the hematopoietic stem cell niche (27),
177 providing precedent for functionally significant KITL production by stellate cells. KITL-positive
178 mesenchyme in the bone marrow express the leptin receptor (LEPR), and we detected low levels
179 of *Lepr* expression among normal PSCs by scRNA-seq (Supplementary Figure S2B). We
180 validated these findings by isolating primary PSCs from healthy pancreas tissue and activating
181 them to a CAF phenotype in culture: These cells expressed *Kitl* and *Lepr* in their normal tissue
182 state but progressively lost expression of both factors upon activation to a CAF-like state (Figure
183 2D, Supplementary Figure S2C & S2D). We next validated expression of *Kitl* in intact murine
184 pancreas tissue. By RNA *in situ* hybridization (ISH, due to lack of specific antibodies, using
185 branched cDNA hybridization), we detected *Kitl* expression in mesenchymal cells of normal
186 pancreas tissue which share markers with PSCs, while *Kitl* expression was lost among CAFs in
187 PDAC (Figure 2E). We also combined RNA ISH for *Kitl* (here using RNAscope, compatible with
188 protein co-staining) with immunohistochemistry (IHC) for GFP on pancreas tissue from
189 *Rosa26^{mTmG/+};Fabp4-Cre* mice and confirmed *Kitl* expression in fate-mapped PSCs. Specificity of
190 our *Kitl* probe was confirmed by reduction in mesenchymal *Kitl* signal in pancreas tissues from
191 *Kitl^{fllox/fllox};Fabp4-Cre* mice (Supplementary Figure S2E). We extended these analyses to human
192 pancreas tissue, and performed RNA ISH for *KITL* and mesenchymal marker *VIM*. While benign
193 human pancreas harbored *KITL*-positive mesenchyme, CAFs within human PDAC lost *KITL*
194 expression, consistent with observations in mice (Figure 2F). As perivascular mesenchyme is a
195 critical source of KITL in other tissues (22, 27), we assessed the spatial distribution of
196 mesenchymal *Kitl* expression by combining *Kitl* RNA ISH with IHC for CD31 and GFP on pancreas
197 tissues from *Rosa26^{mTmG/+};Fabp4-Cre* mice. We found that PSCs express *Kitl* in both perivascular
198 regions and when not adjacent to endothelial cells (Figure 2G), suggested that KITL from PSCs
199 is poised to signal to multiple neighboring cell types. To assess the stage of pancreatic
200 tumorigenesis at which mesenchymal *Kitl* expression is lost, we combined RNA ISH for *Kitl* and
201 IHC for GFP (to indicate PSCs and PSC-derived CAFs) on tissues from *Kras^{FSF-}*
202 *G12D/+;Trp53^{FRT/+};Pdx1-FlpO;Rosa26^{mTmG/+};Fabp4-Cre* mice and noted retention of *Kitl* expression
203 among GFP-positive stromal cells associated with low-grade PanIN lesions identified by a
204 pathologist (Figure 2H), suggesting that loss of stromal *Kitl* accompanies late stages of pancreatic

205 tumorigenesis. Expression of *Kitl* by some GFP-negative cells was noted within these areas of
206 low-grade PanIN as well. Together, these analyses revealed expression of *Kitl* by a lineage of
207 healthy pancreatic mesenchyme in mice and humans which is lost upon transition to a CAF
208 phenotype in invasive cancer.

209
210 We next addressed the functional significance of KITL in pancreatic mesenchyme, and assessed
211 the consequence of stromal KITL loss for tissue homeostasis. First, we questioned the cell-
212 intrinsic impact of KITL signaling on pancreatic mesenchymal cells. To address this, we generated
213 loss- and gain-of-function systems in cell culture by knocking down or overexpressing *Kitl* in
214 immortalized PSCs (28) using shRNA or introduction of the *Kitl* ORF, respectively (Supplementary
215 Figure S3A). PSCs in culture express low but detectable levels of *Kitl* (Figure 2D), so we reasoned
216 that gene expression changes observed with *Kitl* overexpression would reflect downstream
217 transcriptional programs in healthy mesenchyme while *Kitl* knockdown would reflect
218 consequences of gene expression changes upon transition to a CAF state. In culture, PSCs
219 express low but detectable levels of *Kit* (encoding c-KIT) (Supplementary Figure S3B), the
220 paracrine signaling partner for KITL, such that PSC monoculture seemed a reasonable *in vitro*
221 model to begin assessing how KITL signaling impacts pancreatic mesenchyme. To this end, we
222 analyzed the transcriptional profiles of *Kitl*-knockdown and *Kitl*-overexpressing PSCs, together
223 with appropriate controls, by RNA-seq. We prioritized gene expression changes resulting from
224 *Kitl* overexpression as this cell line is activated and therefore CAF-like, though *Kitl* knockdown
225 was indeed achievable. Restoring *Kitl* expression caused upregulation of genes involved in cell
226 adhesion and extracellular matrix or collagen organization, including integrins, laminins,
227 cadherins, and protocadherins (Figure 3A & 3B), suggesting potential involvement of stromal KITL
228 in regulation of normal tissue architecture. Conversely, *Kitl* knockdown led to upregulation of
229 genes involved in inflammatory processes, including genes involved in complement or interferon
230 signaling, together with downregulation of cell adhesion genes (though many of the genes
231 positively regulated by *Kitl* signaling were expressed at a very low level in control cells and were
232 not significantly downregulated further upon *Kitl* knockdown) (Supplementary Figure S3C & S3D).
233 These results suggested that mesenchymal KITL may promote pancreas tissue homeostasis,
234 prompting us to move into *in vivo* modeling of KITL function.

235
236 To assess the relevance of mesenchymal KITL signaling for pancreas tissue architecture, we
237 analyzed the consequences of conditional *Kitl* loss using *Kitl^{fllox/fllox};Fabp4-Cre* mice compared to
238 *Fabp4-Cre* controls in the settings of homeostasis and tissue injury. First, we analyzed these

239 tissues under normal, homeostatic conditions, and crossed in a *Rosa26^{mTmG/+}* allele to enable
240 visualization of PSCs based on GFP expression in these tissues. Based on our transcriptional
241 profiling results, we compared tissue microenvironments in *Rosa26^{mTmG/+};Kitl^{flox/flox};Fabp4-Cre*
242 mice compared to *Rosa26^{mTmG/+};Fabp4-Cre* controls using co-detection by indexing (CODEX), a
243 barcode-based, multiplexed imaging approach (29). While total VIM-positive and CD31-positive
244 cell abundance was not different between genotypes (Supplementary Figure S4A & S4B), we
245 observed clear changes to the perivascular niche with loss of mesenchymal *Kitl* including an
246 increase in GFP-positive mesenchyme adjacent to endothelial cells (Figure 3C). We also
247 observed an increase in CD45-positive leukocytes within normal pancreas tissue when stromal
248 *Kitl* was perturbed (Figure 3D). We also noted a trend towards decreased α -SMA-positive, VIM-
249 positive cells with *Kitl* perturbation (Supplementary Figure S4C)—as fibroblasts are α -SMA-
250 negative in normal pancreas tissue, this likely reflects a reduction in contractility of vascular
251 smooth muscle cells. To assess potentially cellular receivers of mesenchymal KITL which
252 participate in paracrine signaling, we stained pancreas tissues from *Rosa26^{mTmG/+};Fabp4-Cre*
253 mice for GFP, VIM, and KITL receptor KIT. We found that KIT-positive cells were found adjacent
254 to GFP-positive mesenchyme, consistent with the potential for cell-cell communication (Figure
255 3E). As PSCs are localized in perivascular regions as well as next to pancreatic epithelium, but
256 KIT-positive cells were few in number in pancreas tissue, we reasoned that acinar cells were
257 unlikely to be the cellular source of KIT but that CD31-positive endothelial cells and cytokeratin-
258 high ductal epithelial cells may be relevant KIT-positive cell populations. Consistent with this
259 notion, IHC demonstrated KIT expression by sub-populations of ductal epithelial cells and few
260 endothelial cells (Figure 3F & 3G). To confirm these results, we analyzed KIT expression by flow
261 cytometry with co-stains for CD45 (immune cells), CD31 (endothelial cells), or EpCAM (epithelial
262 cells), reasoning that KIT-positive cells negative for these three additional markers represent KIT-
263 positive mesenchyme. KIT-positive cells were found in the EpCAM-positive fraction, consistent
264 with a ductal epithelial identity, and were rarely but measurably positive for CD31 or CD45
265 (Supplementary Figure S4D & S4E), consistent with our IHC. We also noted a KIT-expressing
266 population negative for these markers, which may be a population of mesenchymal cells
267 expressing KIT at too low a level for detection by IHC. We also note that the fairly high proportion
268 of KIT-positive cells among live cells in our flow cytometry experiments likely reflects substantial
269 acinar cell death during preparation of single cell suspensions, as acinar cells appear to be
270 negative for KIT and we have likely therefore enriched for KIT-positive cells. In light of measurable
271 albeit modest differences to tissue structure upon loss of mesenchymal *Kitl*, we assessed the
272 consequences of this KITL pool in the setting of tissue damage. For this, we subjected

273 *Kitl^{fllox/fllox};Fabp4-Cre* mice and *Fabp4-Cre* controls to acute pancreatitis by administering repeated
274 injections of the cholecystokinin analog caerulein, or saline as a vehicle control. As expected, in
275 control mice, caerulein induced a mild inflammation characterized by edema and leukocyte
276 accumulation evident by hematoxylin and eosin staining (Figure 3H). However, in *Kitl* conditional
277 knockout mice, caerulein led to far more pronounced tissue inflammation, as well as greater
278 alterations to the epithelial compartment which we speculated may represent metaplasia or
279 altered epithelial plasticity. To assess this, we co-stained tissues from caerulein-treated mice with
280 amylase (acinar cell marker) and pan-cytokeratin (ductal cell marker), which indicated an increase
281 in ductal marker expression in the inflamed *Kitl* conditional knockout mice (Figure 3I) along with
282 evidence of amylase/pan-cytokeratin co-staining of individual cells. Together, these results
283 implicate mesenchymal KITL in regulation of pancreas tissue homeostasis such that KITL
284 downregulation promotes inflammation and perturbation of normal tissue architecture.

285
286 We next addressed the potential of stromal KITL to regulate pancreatic tumor growth. We
287 performed orthotopic implantation of KPC-derived PDAC cells from a pure C57BL/6J background
288 into syngeneic *Kitl^{fllox/fllox};Fabp4-Cre* mice or *Fabp4-Cre* controls. Despite the aggressive nature of
289 this mouse model, we found that loss of mesenchymal *Kitl* significantly accelerated tumor growth
290 (Figure 4A) and increased tumor weights and tumor burden at experimental endpoint (Figure 4B
291 & 4C). We then repeated these experiments using moribundity as an experimental endpoint
292 instead of a fixed timepoint. Consistent with the tumor growth measurements, survival studies
293 revealed that loss of mesenchymal *Kitl* significantly shortened survival compared to mice in KITL-
294 expressing hosts (Figure 4D). We characterized the mesenchymal compartment of these tumors
295 by staining for PDPN (pan-CAF marker) and α -SMA (myofibroblast-like CAF marker) and found
296 similar CAF abundance in tumors across genotypes (Figure 4E), consistent with the notion that
297 mesenchymal KITL regulates tissue homeostasis but is lost in an established tumor
298 microenvironment. As implantable models involve introduction of cells which have already
299 undergone malignant transformation into pancreas tissue, these results suggest that
300 mesenchymal KITL expression represents a tissue barrier to PDAC progression at least in part
301 independent of epithelial cell-intrinsic tumor suppression mechanisms.

302

303 Discussion

304

305 In this study, we provide evidence that a cell population in normal pancreatic mesenchyme
306 expresses KITL/SCF; that stromal downregulation of KITL is an accompanying feature of

307 pancreatic tumorigenesis, as CAFs derived from these KITL-positive cells retain a lineage label
308 but do not retain KITL expression; and that, functionally, stromal KITL is a barrier to tumor
309 progression in pancreas tissue. The recent reports of abundant, *KRAS*-mutant, pre-invasive
310 lesions throughout examined cohorts of PDAC-free human pancreas tissues (19, 20) compared
311 to the relatively low frequency of PDAC across the general population indicates the pervasive
312 relevance of tumor suppression mechanisms in the adult pancreas. These mechanisms likely
313 include epithelial cell-intrinsic mechanisms promoting, among other things, genome stability and
314 susceptibility to immune surveillance; functions of the immune system, potentially including
315 clearance of highly mutated epithelial cells with tumorigenic potential; and functions of the non-
316 immune stroma. Within the non-immune stroma, mesenchymal components—fibroblasts in
317 particular—are broadly implicated in maintenance of normal tissue structure or architecture as
318 well as support of tissue homeostasis via production of soluble factors, basement membrane, and
319 ECM components. Perturbation of fibroblast phenotypes to an activated state is an anatomically
320 conserved feature of many solid cancers and some inflammatory conditions (25), and while
321 activated fibroblasts in disease states generally express ECM components and immune-
322 modulatory factors, granular features of fibroblast activation programs are tissue- and disease-
323 specific. Though activated fibroblasts in cancer carry out diverse functions to promote tumor
324 progression, normal fibroblasts serve to restrain tumor formation in promoting the ordered tissue
325 structure that must be overcome to enable cancer formation or progression. We propose KITL as
326 a tumor-restraining stromal mechanism in the pancreas, raising the possibility that specific
327 effectors downstream of KITL signaling may hold utility for cancer progression. Future efforts will
328 aim to investigate the significance of KITL signaling in the specific context of low-grade PanIN
329 lesions, as these are the lesions found in adult human pancreas (19, 20).

330
331 While our study was restricted to the pancreas, these findings fit within a broader context of prior
332 studies implicating mesenchymal KITL and/or LEPR-positive mesenchyme as critical regulators
333 of tissue homeostasis and normal tissue function in diverse organ sites. As briefly discussed
334 above, LEPR-positive mesenchymal cells in the bone marrow associate tightly with endothelial
335 cells and form a niche critical for hematopoietic stem cells (22). Interestingly, upon tissue damage
336 such as irradiation or chemotherapy requiring regeneration of hematopoietic stem cells, LEPR-
337 positive mesenchymal cells differentiate into adipocytes which in turn produce KITL to enable a
338 functional niche and support hematopoietic regeneration (30). Complementary mesenchymal and
339 signaling components were recently shown to support normal tissue homeostasis and suppress
340 inflammation in brown adipose tissue (BAT): LEPR-positive mesenchyme supports adaptive

341 thermogenesis and restrains inflammation in BAT (23), while endothelial cell-derived KITL/SCF
342 signals to KIT on brown adipocytes to promote homeostatic lipid accumulation when
343 thermogenesis is inhibited (31). As the stellate cells under investigation in our study are also lipid-
344 storing cells, these studies raise the possibility that lipid-storing stromal cells engage KITL
345 signaling to promote tissue homeostasis and limit inflammation more broadly across organs.

346

347 **Methods**

348

349 **Human tissue samples**

350 All experiments with human patient-derived material were performed with approval of the Oregon
351 Health & Science University and Memorial Sloan Kettering Cancer Center Institutional Review
352 Boards. Sections from formalin-fixed, paraffin-embedded human PDAC patient tissue samples
353 harboring benign adjacent pancreas tissue were donated to the Oregon Pancreas Tissue Registry
354 program with informed written patient consent in accordance with full approval by the OHSU
355 Institutional Review Board, or were obtained with informed consent of biospecimen collection with
356 full approval by the MSKCC Institutional Review Board.

357

358 **Animals**

359 All experiments involving mice were reviewed and overseen by the Institutional Animal Care and
360 Use Committees at OHSU and MSKCC in accordance with National Institutes of Health guidelines
361 for the humane treatment of animals. Male and female mice were used for all experiments, with
362 ages specified in the experimental sections to follow. Littermate controls were used whenever
363 possible. Animals included in pancreatitis and PDAC experiments were assessed daily based on
364 score sheets with criteria including body condition scoring and physical examination to ensure
365 humane treatment. Orthotopic tumors were grown to a maximum diameter of 1.0 cm based on
366 institutional guidelines. Maximal burden was not exceeded with any animal. The following mice
367 were used in this study, all purchased from the Jackson Laboratory: C57BL/6J (000664),
368 *Rosa26^{mTmG}* (007676), *Fabp4-Cre* (005069), *Kitl^{fllox}* (017861), *Trp53^{flr}* (017767), *Kras^{FSF-G12D}*
369 (023590). The *Pdx1-FlpO* mouse strain was kindly provided by Dr. Michael Ostrowski (Medical
370 University of South Carolina).

371

372 **Pancreatitis induction**

373 Acute pancreatitis was induced in male and female mice at 8 weeks of age by intraperitoneal
374 injection of caerulein (80 µg/kg, Sigma-Aldrich C9026) 8 times per day with 1 h between injections,

375 on 2 consecutive days. Mice were then euthanized 2 days after the final caerulein injection and
376 pancreata were collected.

377

378 **Orthotopic transplantation of PDAC cells**

379 The 6419c5 and FC1245 cell lines were derived from autochthonous PDAC in the $Kras^{LSL-}$
380 $G12D/+;Trp53^{LSL-R172H/+};Pdx1-Cre$ genetically engineered mouse model of pure C57BL/6J
381 background, and were kindly provided by Dr. Ben Stanger (University of Pennsylvania) and Dr.
382 David Tuveson (Cold Spring Harbor Laboratory), respectively. Male or female mice at 8-10 weeks
383 of age were anesthetized and orthotopically implanted with 5×10^4 (6419c5) or 5×10^3 (FC1245)
384 PDAC cells in a 50% Matrigel solution into the body of the pancreas. Tumor progression was
385 monitored longitudinally by high-resolution ultrasound using the Vevo 2100 imaging system. Mice
386 were euthanized and tumors collected either when the first mouse of the experiment reached
387 humane endpoint, or at different time points when each individual mouse in the experiment
388 reached humane endpoint.

389

390 **Single-cell RNA-seq**

391 **Cell isolation**

392 To isolate healthy PSCs, pancreata were harvested from $Rosa26^{mTmG/+};Fabp4-Cre$ mice at 6-9
393 weeks of age, trimmed to remove any associated adipose tissue, minced with scissors, digested
394 with 0.02% Pronase (Sigma-Aldrich), 0.05% Collagenase P (Sigma-Aldrich), and 0.1% DNase I
395 (Sigma-Aldrich) in Gey's balanced salt solution (GBSS; Sigma-Aldrich) at 37°C for 10 minutes.
396 Pancreata were further mechanically dissociated via serological pipette before returning to
397 chemical dissociation at 37°C for 5 minutes. The resulting cell suspension was filtered through a
398 100 μ m cell strainer nylon mesh. Cells were washed with GBSS, pelleted, and subject to red blood
399 cell lysis via ACK lysis buffer (Thermo Fisher Scientific) for 3 minutes at room temperature. Then,
400 cells were washed in cold FACS buffer (PBS containing 2% FBS), pelleted, and resuspended in
401 FACS buffer. Cells were kept on ice as a single-cell suspension, then GFP-positive cells were
402 isolated by FACS using a BD FACSAria III or BD FACSymphony S6.

403

404 To isolate CAFs, 8-week-old $Rosa26^{mTmG/+};Fabp4-Cre$ mice were orthotopically implanted with
405 FC1245 PDAC cells as described above. At 21 days post-implantation, pancreata were
406 harvested, and any apparent normal pancreas tissue was trimmed away from the PDAC
407 specimen. Tumors were briefly minced, placed in digestion media (DMEM with 1 mg/ml
408 Collagenase IV, 0.1% soybean trypsin inhibitor, 50 U/ml DNase, and 0.125 mg/ml Dispase), and

409 incubated at 37°C for 1 h. Whole tissue digests were centrifuged at 450 g for 5 min, then
410 resuspended in 10 ml pre-warmed 0.25% Trypsin and incubated at 37°C for 10 min. Cold DMEM
411 (10 ml) was added to the suspension, which was then passed through a 100 µm cell strainer.
412 Cells were centrifuged as above, washed with DMEM containing 10% FBS and centrifuged again,
413 then centrifuged as above and resuspended in 1 ml ACK red cell lysis buffer. Cells were incubated
414 at room temperature for 3 minutes, then 9 ml FACS buffer added and cells centrifuged as above.
415 Pelleted cells were counted and resuspended at 1 x 10⁷ cells/ml in FACS buffer, CD16/CD32 Fc
416 block (BD 553141) added 1:20 and incubated at room temperature for 2 min, then biotinylated
417 PDPN antibody (BioLegend 127404) was added 1:200. Cell suspensions were incubated on ice
418 for 30 min. Cold FACS buffer was added, cells centrifuged at 300 g for 5 min at 4°C, and cell
419 pellets were resuspended in 500 µl cold FACS buffer containing 1:1000 APC-streptavidin (BD
420 554067) and incubated for 30 min on ice protected from light. Cold FACS buffer (2 ml) was added,
421 cells were pelleted as above and resuspended in cold FACS buffer containing SYTOX Blue Dead
422 Cell Stain (Invitrogen S34857). Cells were incubated for 30 min on ice, washed with FACS buffer,
423 pelleted, and resuspended in cold FACS buffer. GFP-positive PDPN-positive cells were isolated
424 by FACS using a BD FACSAria III or BD FACSymphony S6.

425

426 ***Sequencing and analysis***

427 The isolated pancreatic mesenchymal cells were immediately used for single-cell RNA-seq library
428 preparation. Single cell capture and cDNA library generation were performed using the 10x
429 Genomics Chromium single-cell 3' library construction kit v2 (120267) according to the
430 manufacturer's instructions. Libraries were pooled prior to sequencing based on estimated cell
431 number in each library per flow cytometry cell counts. Sequencing was performed on the Illumina
432 NovaSeq 6000 platform at the OHSU Massively Parallel Sequencing Shared Resource,
433 sequencing 20,000 read pairs per cell.

434

435 We aligned the sequenced reads to the mm10 mouse reference genome, and the unique
436 molecule identifier (UMIs) for each gene in each cell were counted using the Cell Ranger (10x
437 Genomics). Then, we imported the resulting gene expression matrices into R (version 4.0.3) and
438 analyzed the data using the Seurat (32) pipeline (version 4.0.1). Genes had to be expressed in at
439 least three cells to be considered for downstream analyses. Cells were filtered to retain those that
440 contained at least 1,000 minimum unique genes expressed, no more than 5,000 unique genes,
441 more than 200 total UMIs, and less than 10% of counts mapped to the mitochondrial genome.
442 Batch correction was performed to integrate the samples from different conditions using the

443 reciprocal PCA (RPCA) integration workflow (33) within Seurat. The first 30 principal components
444 were selected for downstream analysis, based on the elbow point on the plot of standard
445 deviations of principal components. UMAP was generated using the RunUMAP function with the
446 same first 30 principal components used in clustering analysis.

447

448 We performed pseudotime trajectory analysis to elucidate the differentiation pathways of normal
449 pancreatic and cancerous cells using Monocle 3 (v.1.3.7) (34). To achieve this, we first integrated
450 our single-cell RNA-seq datasets using Harmony (v.0.1.1) (35) to correct for batch effects,
451 enabling a unified visualization of cellular heterogeneity across samples. Subsequent trajectory
452 inference with Monocle 3 was conducted using default parameters to order cells in pseudotime,
453 thus highlighting the dynamic progression of cellular states. To visualize gene expression patterns
454 along the trajectories, we utilized the 'plot_cell_trajectory' function, focusing on the expression of
455 *Kitl* in the harmony-adjusted dimensional space.

456

457 **Mouse pancreatic stellate cells (mPSCs) isolation**

458 Primary mPSCs were isolated from wild-type C57BL/6J (000664) mice from The Jackson
459 Laboratory at 8-9 weeks of age. Our isolation protocol is adapted from previously described
460 methods (36, 37) with some minor modifications. Healthy pancreatic tissues from eight male mice
461 were pooled, trimmed, and digested in Hank's balanced salt solution (HBSS; Sigma Aldrich,
462 H8264) containing 0.5 mM of magnesium chloride hexahydrate ($MgCl_2 \times 6H_2O$; Sigma Aldrich,
463 M9272), 10 mM HEPES (Cytiva, SH30237.01), 0.13% Collagenase P (Roche, 11213873001),
464 0.1% protease (Sigma Aldrich, p5417), and 0.001% DNase (Roche, 04716728001) for 7 minutes
465 in shaking water bath (120 cycles/min) at 37°C. Remaining connective and adipose tissues were
466 removed before the second incubation at 37°C in a shaking water bath (80 cycles/min) for an
467 additional 7 minutes. Digested tissues were then filtered through a 250 μm nylon mesh (Thermo
468 Fisher Scientific, 87791) and centrifuged at 450 g for 10 minutes at 4°C. The cell pellet was
469 washed in Gey's balanced salt solution (GBSS) containing 120 mM salt (NaCl; Sigma Aldrich,
470 S3014) and 0.3% BSA (Fisher Scientific, BP9703100) before repeating the centrifugation step
471 above. Upon removing the wash buffer, cells were resuspended in GBSS + NaCl containing 0.3%
472 BSA, to which equal volume of 28.7% solution of Nycodenz (ProteoGenix, 1002424) in GBSS -
473 NaCl were added and mixed well. The cell suspension in Nycodenz is then gently layered beneath
474 GBSS containing 120 mM NaCl and 0.3% BSA using a long needle and subjected to centrifugation
475 at 1400xg for 20 minutes at 4°C. Primary quiescent PSCs were carefully harvested from the
476 interface using sterile pipette and washed with GBSS + NaCl containing 0.3% BSA. Cells were

477 pelleted and plated into multiple wells of a 6-well dish in Iscove's modified Dulbecco's medium
478 (IMDM; Cytiva, SH30228.02) containing 10% FBS (VWR, 97068-085) and 1% Antibiotics-
479 Antimycotic (Thermo Fisher Scientific, 15240-062). Cell culture was maintained in a humidified
480 atmosphere at 37°C with 5% CO₂.

481

482 **Stable *Kitl* knock down and overexpression in pancreatic stellate cells**

483 *Kitl* knock down (*shKitl*) and overexpression (*Kitl* OE) mPSC-1 cell lines were generated using
484 Mission Lentiviral shRNA (Millipore Sigma, Clone ID: TRCN0000067872) and *Kitl* open reading
485 frame lentivirus (Genecopoeia, EX-Mm03868-Lv158) respectively. Vector PLKO.1 Neo (*shCtrl*;
486 Addgene, 13425) and *Egfp* open reading frame (*Egfp* OE; Genecopoeia, EX-EGFP-Lv158) were
487 included as controls. Immortalized mPSC-1 cells were transduced with specified lentiviral
488 particles for 48 hours prior to selection with 1 mg/mL Geneticin (Fisher Scientific, 10131035) for
489 4 days. KITL protein and transcript expression were then quantified using qPCR and ELISA to
490 assess silencing and overexpression efficiency. Stable cells were maintained in a humidified
491 atmosphere at 37°C with 5% CO₂ and routinely passed in DMEM (Thermo Fisher Scientific,
492 11965118) containing 10% FBS (VWR, 97068-085) 1 mM sodium pyruvate (Thermo Fisher
493 Scientific, 11360070), and 1% Antibiotics-Antimycotic (Thermo Fisher Scientific, 15240-062).

494

495 **RNA-sequencing of *shKitl* and *Kitl* ORF pancreatic stellate cells**

496 Total RNA was isolated using RNeasy Microkit (Qiagen, 74004) per manufacturer's instructions
497 and quantified using NanoDrop microvolume spectrophotometer before submission for bulk RNA-
498 sequencing. RNA library preparation, sequencing, and analysis were conducted at Azenta Life
499 Sciences (South Plainfield, NJ, USA) as follows. Total RNA samples were quantified using Qubit
500 2.0 Fluorometer (Life Technologies, Carlsbad, CA, USA) and RNA integrity was checked using
501 Agilent TapeStation 4200 (Agilent Technologies, Palo Alto, CA, USA). ERCC RNA Spike-In Mix
502 (Cat: #4456740) from ThermoFisher Scientific, was added to normalized total RNA prior to library
503 preparation following manufacturer's protocol. Total RNA underwent polyA selection and RNA
504 sequencing libraries preparation using the NEBNext Ultra II RNA Library Prep Kit for Illumina
505 using manufacturer's instructions (NEB, Ipswich, MA, USA). Briefly, mRNAs were initially enriched
506 with Oligod(T) beads. Enriched mRNAs were fragmented for 15 minutes at 94 °C. First strand
507 and second strand cDNA were subsequently synthesized. cDNA fragments were end repaired
508 and adenylated at 3'ends, and universal adapters were ligated to cDNA fragments, followed by
509 index addition and library enrichment by PCR with limited cycles. The sequencing library was
510 validated on the Agilent TapeStation (Agilent Technologies, Palo Alto, CA, USA), and quantified

511 by using Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR (KAPA
512 Biosystems, Wilmington, MA, USA). The sequencing libraries were multiplexed and clustered
513 onto a flowcell on the Illumina NovaSeq instrument according to manufacturer's instructions. The
514 samples were sequenced using a 2x150bp Paired End (PE) configuration at an average of 30
515 million reads per sample. Image analysis and base calling were conducted by the NovaSeq
516 Control Software (NCS). Raw sequence data (.bcl files) generated from Illumina NovaSeq was
517 converted into fastq files and de-multiplexed using Illumina bcl2fastq 2.20 software. One mis-
518 match was allowed for index sequence identification.

519
520 After investigating the quality of the raw data, sequence reads were trimmed to remove possible
521 adapter sequences and nucleotides with poor quality. The trimmed reads were mapped to the
522 reference genome GRCm38.91 (mm10) available on ENSEMBL using the STAR aligner v.2.5.2b.
523 The STAR aligner is a splice aligner that detects splice junctions and incorporates them to help
524 align the entire read sequences. BAM files were generated as a result of this step. Unique gene
525 hit counts were calculated by using feature Counts from the Subread package v.1.5.2. Only unique
526 reads that fell within exon regions were counted. The gene hit counts table was used for
527 downstream differential expression analysis. Using DESeq2, a comparison of gene expression
528 between the groups of samples was performed. The Wald test was used to generate p-values
529 and Log2 fold changes. Genes with adjusted p-values < 0.05 and absolute log2 fold changes > 1
530 were called as differentially expressed genes for each comparison. Volcano plot visualization of
531 significant DEGs were performed in Galaxy (38) using the ggplot2 R package. Significant gene
532 labels from top gene ontologies categories were included.

533 Functional enrichment analysis was performed using enrichR (39) on the statistically significant
534 set of genes by implementing Fisher exact test (GeneSCF v1.1-p2). Significance of tests was
535 assessed using adjusted p-values defined by enrichR. Enrichment bar plots were generated using
536 srPlot (40) to include Top 10 upregulated and downregulated gene ontology categories.

537

538 **Immunohistochemistry, immunofluorescence, and lipid staining**

539 ***Mouse and human tissue sample staining***

540 Standard protocols were performed for IHC. Briefly, tissue samples were fixed overnight in 10%
541 neutral-buffered formalin (Sigma-Aldrich, HT501128-4L) and submitted to MSKCC Laboratory of
542 Comparative Pathology or Molecular Cytology Core Facility for paraffin embedding, sectioning
543 and H&E sectioning. Sectioned tissues were deparaffinized using CitriSolv (Fisher Scientific, 22-
544 143-975) and rehydrated in ethanol series (Decon labs, 2701) before undergoing antigen retrieval

545 using citrate or tris based antigen unmasking solution (Vector laboratories, H3300, H3301). The
546 slides were then blocked with 8% BSA (Fisher Bioreagents, BP9703100) for 1 hour at room
547 temperature and incubated in primary antibodies at 4°C overnight. Primary antibodies for α SMA
548 (Cell Signaling Technology, 19245S), PDPN (eBio 8.1.1 Invitrogen, 14538182), GFP (Thermo
549 Fisher, A10262; Abcam, ab1218; Rockland Immunochemicals, 600-101-215), pan-cytokeratin
550 (Thermo Fisher Scientific, MA5-13156), CD31 (R&D AF3628 or Abcam ab7388), biotinylated anti-
551 c-Kit (R&D BAF1356), Vimentin (Cell Signaling Technology 5741 D21H3 XP), or pancreatic
552 amylase (Thermo Scientific PA5-25330) were diluted at 1:200-1:400 in 8% BSA in PBS. The next
553 day, slides were washed with PBS (Biotum, 22020) and incubated in α -chicken Alexa Fluor 488
554 (Thermo Fisher Scientific, A32931), α -rabbit Alexa Fluor 647 (Fisher Scientific, A21245), α -Syrian
555 hamster Alexa Fluor 647 (Abcam, ab180117), or α -mouse Alexa Fluor 555 (Fisher Scientific,
556 A21424) secondary antibodies at 1:200-1:400 dilution for 1 hour at room temperature. Tissue
557 slides were washed with PBS and mounted with Vectashield mounting media containing DAPI
558 (Vector laboratories, H-1200-10).

559
560 All images were acquired on a Carl Zeiss LSM880 laser-scanning confocal inverted microscope
561 using 20x, 40X, or 63X objective. Whole slide scans were completed by MSKCC Molecular
562 Cytology Core Facility. Image analysis was performed using QuPath quantitative pathology and
563 FIJI/ImageJ open source software. Where applicable, co-localization analysis was performed
564 using the JaCop plugin in ImageJ.

565 566 ***Cell staining and imaging***

567 Cells seeded in chamber slides were fixed in 4% paraformaldehyde for 15 minutes and
568 permeabilized with 0.1% Triton X-100 for 10 minutes before undergoing blocking in 5% BSA for 1
569 hour at room temperature. Sample slides were then probed with α SMA primary antibodies
570 (ThermoFisher, MA5-11547) overnight at 4°C followed by standard Alexa Fluor 647-conjugated
571 secondary antibody (Fisher Scientific, A21235) incubation for an hour at room temperature. Upon
572 repeating standard washing steps, slides were mounted for imaging using Vectashield mounting
573 media containing DAPI (Vector laboratories, H-1200-10). For lipid staining, cells seeded in
574 chamber slides were stained with Nile Red (MCE, HY-D0718) at 1 μ M final working concentration
575 for 10 minutes and counterstained with DAPI (Thermo Fisher Scientific, 62248). Nile Red signals
576 were detected at excitation/emission wavelengths 559 nm/ 635 nm.

577 578 ***Two-plex fluorescence *in situ* hybridization***

579 Transcript expression on tissues, except where RNAscope was indicated, was performed using
580 the Thermo Fisher Scientific ViewRNA ISH Tissue Assay kit (two plex) for use on mouse and
581 human tissue samples. Briefly, samples were first permeabilized with controlled protease
582 digestion, followed by incubation with proprietary probe-containing solution, according to the
583 manufacturer's instructions. During incubation, samples had to remain fully submerged. After
584 hybridization with the probe, samples were washed, followed by sequential hybridization with the
585 preamplifier and amplifier DNA. In accordance with the manufacturer's instructions, hybridizations
586 were performed with the preamplifier, amplifier and fluorophore. Mounting medium with DAPI
587 (Vectashield Hardset mounting media with DAPI) was used to mount samples.

588

589 **RNAscope combined with immunohistochemistry**

590 Paraffin-embedded tissue sections were cut at 5 μ m and kept at 4°C. Samples were loaded into
591 Leica Bond RX, baked for 30 mins. at 60°C, dewaxed with Bond Dewax Solution (Leica, AR9222),
592 and pretreated with EDTA-based epitope retrieval ER2 solution (Leica, AR9640) for 15 mins. at
593 95°C. The probe mKitL (Advanced Cell Diagnostics, ready to use, no dilution, 423408) was
594 hybridized for 2hrs. at 42°C. Mouse PPIB (ACD, Cat# 313918) and dapB (ACD, Cat# 312038)
595 probes were used as positive and negative controls, respectively. The hybridized probes were
596 detected using RNAscope 2.5 LS Reagent Kit – Brown (ACD, Cat# 322100) according to
597 manufacturer's instructions with some modifications (DAB application was omitted and replaced
598 with Fluorescent CF594/Tyramide (Biotium,92174) for 20 mins. at RT).

599

600 After the run was finished, slides were washed in PBS and incubated in 5 μ g/ml 4',6-diamidino-2-
601 phenylindole (DAPI) (Sigma Aldrich) in PBS for 5 min, rinsed in PBS, and mounted in Mowiol 4-
602 88 (Calbiochem). Slides were kept overnight at -20°C before imaging.

603

604 After the slides were scanned, the coverslips were removed and slides were loaded into Leica
605 Bond RX for double IF staining. Samples were pretreated with EDTA-based epitope retrieval ER2
606 solution (Leica, AR9640) for 20 mins. at 100°C. The double antibody staining and detection were
607 conducted sequentially. The primary antibodies against GFP (2ug/ml, chicken, abcam, ab13970
608) and CD31 (CD31/A647 (0.08, rb, abcam, ab182981) were incubated for 1h at RT. For rabbit
609 antibodies, Leica Bond Polymer anti-rabbit HRP (included in Polymer Refine Detection Kit (Leica,
610 DS9800) was used, for the chicken antibody, a rabbit anti-chicken (Jackson
611 ImmunoResearch303-006-003) secondary antibodies were used as linkers for 8 min before the
612 application of the Leica Bond Polymer anti-rabbit HRP for 8 min at RT. The Leica Bond Polymer

613 anti-rabbit HRP secondary antibody was applied followed by Alexa Fluor tyramide signal
614 amplification reagents (Life Technologies, B40953 and B40958) were used for IF detection. After
615 the run was finished, slides were washed in PBS and mounted in Mowiol 4–88 (Calbiochem).
616 Slides were kept overnight at -20°C before imaging.

617

618 **CODEX**

619 ***Antibody panel development, CODEX staining and imaging***

620 To construct an antibody panel visualizing pancreatic architecture in FFPE mouse samples using
621 CODEX (29), conventional IHC staining was performed to screen for antibodies binding canonical
622 markers of pancreatic epithelial cells [E-cadherin, Novus Biologicals #NBP2-33006 clone
623 1A4(asm-1); Amylase, Cell Signaling Technology #3796 clone D55H10], endothelial cells (CD31,
624 Cell Signaling Technology #14472 clone 4A2), stromal cells (Vimentin, Cell Signaling Technology
625 #70257 clone D3F8Q; α -SMA, Cell Signaling Technology #77699 clone D8V9E), leukocytes
626 (CD45, Cell Signaling Technology #46173 clone D21H3) and lineage reporter (GFP, Rockland
627 Immunochemicals #600-101-215 polyclonal). Identified antibody clones were then conjugated
628 with oligonucleotide barcodes using Antibody Conjugation Kit (Akoya Biosciences). Prior to
629 CODEX imaging, each conjugated antibody was validated following manufacturer instructions
630 and tissue staining patterning was confirmed with published literature.

631 CODEX staining and imaging was performed as described in user manual
632 (<https://www.akoyabio.com/wp-content/uploads/2021/01/CODEX-User-Manual.pdf>). In brief, 5
633 μ m FFPE pancreas sections were mounted onto 22 mm x 22 mm glass coverslips (Electron
634 Microscopy Sciences) coated in 0.1% poly-L-lysine (Sigma) and stained with using CODEX
635 Staining Kit (Akoya Biosciences). A cocktail of above-conjugated antibodies were incubated with
636 tissue overnight at 4°C. On the next day, fluorescent oligonucleotide-conjugated reporters were
637 combined with Nuclear Stain and CODEX Assay Reagent (Akoya Biosciences) in sealed light-
638 protected 96-well plates (Akoya Biosciences). Automated fluidics exchange and image acquisition
639 were performed using the Akoya CODEX instrument integrated with a BZ-X810 epifluorescence
640 microscope (Keyence) and CODEX Instrument Manager (CIM) v1.30 software (Akoya
641 Biosciences). The exposure times were as follows: E-cadherin, barcode BX006, 600 ms;
642 Amylase, barcode BX031, 250 ms; Vimentin, barcode BX025, 300 ms; α -SMA, barcode BX052,
643 250 ms; CD31, barcode BX002, 350 ms; CD45, barcode BX007, 400 ms; GFP, barcode BX041,
644 250 ms. All images were acquired using a CFI plan Apo I 20 \times /0.75 objective (Nikon). “High
645 resolution” mode was specified in Keyence software to reach a final resolution of 377.44 nm/pixel.

646

647 **Processing of CODEX images and analysis**

648 Image stitching, drift compensation, deconvolution, z-plane selection, and background subtraction
649 were performed using the CODEX processor v1.7 (Akoya Biosciences) per manufacture
650 instruction (<https://help.codex.bio/codex/processor/technical-notes>). Individual channel images
651 were then imported into ImageJ v1.53t for analyses as described below.

652 Total pancreatic areas were annotated by sum of Amylase⁺ and Ecadherin⁺ region. Immune cells
653 were defined by DAPI and CD45 double positivity while vasculature area was annotated by
654 CD31+ region. Vimentin and α -SMA signal were used to mark total and activated fibroblast cells,
655 respectively. GFP positivity was used to track PSC lineage-derived cells.

656

657 **Flow cytometry**

658 To analyze c-KIT expression, normal pancreas tissues were harvested from wild-type C57BL/6J
659 mice aged 6-9 weeks and digested as described above. Following ACK lysis, cells were incubated
660 with CD16/CD32 antibody (BD Biosciences, 553141) to block Fc receptors for 2 minutes at room
661 temperature. Cells were then stained with the following for 30 minutes on ice: SYTOX Blue Dead
662 Cell Stain (Invitrogen S34857); biotinylated m-SCF R/c-KIT antibody (R&D Systems BAF1356).
663 Cells were then washed with cold FACS buffer, pelleted, then stained with PE/Cy7 Streptavidin
664 (Biolegend, 405206), anti-mouse CD31 APC (Invitrogen 17-0311-82), anti-mouse EpCAM
665 (CD326) FITC (Invitrogen 11-5791-82) for 30 minutes on ice, before cells were washed with FACS
666 buffer, pelleted, then resuspended in cold FACS buffer for flow cytometry.

667

668 To analyze epithelial cells, immune cells, and c-KIT, pancreata from C57Bl/6J mice aged 6-9
669 weeks old were harvested and digested as described above. After ACK lysis, cells were incubated
670 with CD16/CD32 antibody (BD Biosciences 553141) for 2 minutes at room temperature. Cells
671 were then stained with SYTOX Blue and a biotinylated c-KIT antibody on ice for 30 minutes on
672 ice, were washed with cold FACS buffer, pelleted, then stained with PE/Cy7 Streptavidin
673 (Biolegend 405206), anti-mouse CD45 PE-Cyanine 5 (Invitrogen 15-0451-82), anti-mouse
674 EpCAM (CD326) FITC (Invitrogen 11-5791-82) for 30 minutes on ice. Cells were washed with
675 FACS buffer, pelleted, then resuspended in cold FACS buffer for flow cytometry.

676

677 **Gene expression analysis by qPCR**

678 Total RNA was isolated using RNeasy Microkit (Qiagen, 74004) per manufacturer's instructions
679 and quantified using NanoDrop microvolume spectrophotometer. 500 ng to 1 μ g of RNA was
680 reverse transcribed using iScript reverse transcriptase supermix (Bio-Rad, 1708841) to produce

681 cDNA. Real-time PCR was performed using Power SYBR Green PCR master mix (Thermo
682 Fisher, 4367659). Gene specific primer pairs were designed using the NCBI Nucleotide database
683 or acquired from Millipore Sigma. Gene expression is normalized to reference gene *Rplp0*. Primer
684 pair sequences were as follows: *Rplp0* Forward 5'-GTGCTGATGGGCAAGAAC-3' Reverse 5'-
685 AGGTCCTCCTTGGTGAAC-3', *mKitl* Forward 5'-TTATGTTACCCCTGTTGCAG-3' Reverse 5'-
686 CTGCCCTTGTAAGACTTGACTG-3', *mKit* Forward 5'-GAGACGTGACTCCTGCCATC-3'
687 Reverse 5'-TCATTCCTGATGTCTCTGGC-3', *mActa2* Forward 5'-
688 AGCCATCTTTCATTGGGATGGA-3' Reverse 5'-CATGGTGGTACCCCTGACA-3'.

689

690 **ELISA quantikine assay**

691 Immortalized parental and sh*Kitl* mPSC-1 cells were seeded into 6 well dish at 3×10^5 confluency
692 in growth media containing DMEM (Thermo Scientific, 11965126), 10% VWR Seradigm FBS
693 (VWR, 97068-085), 1 mM Sodium Pyruvate (Thermo Scientific, 11360070), and 1% Antibiotics-
694 Antimycotic (Thermo Fisher Scientific, 15240-062). Primary PSCs were seeded in 6 well dish at
695 1×10^4 confluency in Iscove's modified Dulbecco's medium (IMDM; Cytiva, SH30228.02)
696 containing 10% FBS (VWR, 97068-085) and 1% Antibiotics-Antimycotic (Thermo Fisher
697 Scientific, 15240-062). Conditioned media were collected at indicated time points and
698 concentrated using Vivaspin Turbo 20 3K MWCO concentrator (Cytiva, 28932358) in accordance
699 with manufacturer's protocol. Concentrated supernatants were quantified using Pierce BCA
700 Protein Assay Kit (Thermo Fisher, 23225) and mouse KITL protein quantification was performed
701 using Mouse SCF Quantikine ELISA Kit (R&D Systems, MCK00) according to manufacturer's
702 protocol.

703

704 **Statistical analysis**

705 No statistical methods were used to predetermine sample sizes. The experiments were not
706 randomized. For animal studies, a minimal number of mice was selected based on preliminary
707 studies, with an effort to achieve a minimum of $n = 3$, mostly $n = 5-10$ mice per treatment group
708 for each experiment. Age-matched mice were selected for experiments. For histological staining
709 quantification, analyses were performed in a blinded fashion. For batch-processed images, image
710 analyses were done in an unbiased manner using image analysis software. Some western blots
711 and RT-qPCR assays were performed by a researcher blind to the experimental hypothesis.
712 Animals were excluded if an animal needed to be removed from an experiment early for reasons
713 seemingly unrelated to tumor burden. All experiments were performed and reliably reproduced at
714 least two independent times. GraphPad Prism 9 was used to generate graphs and for statistical

715 analyses. Groups were tested for normality. Statistical significance was calculated for two
716 unmatched groups by unpaired *t*-test with Welch's correction or Mann-Whitney test. One- or two-
717 way ANOVAs were used for more than two groups as specified, followed by Tukey's multiple
718 comparisons tests. Datasets are presented as mean \pm s.e.m. *P* values under 0.05 were
719 considered significant. Data distribution was assumed to be normal, but this was not formally
720 tested.

721

722 **Acknowledgements**

723

724 We thank Mark Berry, Wenfei Kang, and all members of the Sherman lab for helpful discussion
725 of this work. This study was supported by NIH grants R01 CA229580 and R01 CA250917 (to
726 M.H.S.), NIH grant P01 CA244114 (to M.H.S. and Y.H.), NIH grant R01 GM147365 (to Z.X.), and
727 a Silver Family Innovation Fund Award (to Z.X.). We thank members of the OHSU Histopathology
728 Shared Resource, Advanced Light Microscopy Shared Resource, Flow Cytometry Shared
729 Resource, and Massively Parallel Sequencing Shared Resource for supporting this study, with
730 financial support from NIH-NIH Cancer Center Support Grant P30 CA069533. We also thank
731 members of the MSKCC Flow Cytometry Core, Molecular Cytology Core, and Center of
732 Comparative Medicine & Pathology for supporting this work, with financial support from NIH-NCI
733 Cancer Center Support Grant P30 CA008748.

734

735 **Data availability statement**

736

737 The data generated in this study will be made publicly available in the Gene Expression Omnibus
738 prior to publication.

739

740 **References**

741

- 742 1. Stoker MG, Shearer M, O'Neill C. Growth inhibition of polyoma-transformed cells by
743 contact with static normal fibroblasts. *J Cell Sci.* 1966;1(3):297-310. doi: 10.1242/jcs.1.3.297.
744 PubMed PMID: 4291022.
- 745 2. Brown S, Pineda CM, Xin T, Boucher J, Suozzi KC, Park S, et al. Correction of aberrant
746 growth preserves tissue homeostasis. *Nature.* 2017;548(7667):334-7. Epub 20170802. doi:
747 10.1038/nature23304. PubMed PMID: 28783732; PubMed Central PMCID: PMC5675114.
- 748 3. Pineda CM, Gonzalez DG, Matte-Martone C, Boucher J, Lathrop E, Gallini S, et al. Hair
749 follicle regeneration suppresses Ras-driven oncogenic growth. *J Cell Biol.* 2019;218(10):3212-
750 22. Epub 20190905. doi: 10.1083/jcb.201907178. PubMed PMID: 31488583; PubMed Central
751 PMCID: PMC6781447.

- 752 4. Gallini S, Annusver K, Rahman NT, Gonzalez DG, Yun S, Matte-Martone C, et al. Injury
753 prevents Ras mutant cell expansion in mosaic skin. *Nature*. 2023;619(7968):167-75. Epub
754 20230621. doi: 10.1038/s41586-023-06198-y. PubMed PMID: 37344586; PubMed Central
755 PMCID: PMC10322723.
- 756 5. Blaisdell A, Crequer A, Columbus D, Daikoku T, Mittal K, Dey SK, et al. Neutrophils
757 Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells. *Cancer*
758 *Cell*. 2015;28(6):785-99. doi: 10.1016/j.ccell.2015.11.005. PubMed PMID: 26678340; PubMed
759 Central PMCID: PMC4698345.
- 760 6. Cui C, Chakraborty K, Tang XA, Zhou G, Schoenfelt KQ, Becker KM, et al. Neutrophil
761 elastase selectively kills cancer cells and attenuates tumorigenesis. *Cell*. 2021;184(12):3163-77
762 e21. Epub 20210507. doi: 10.1016/j.cell.2021.04.016. PubMed PMID: 33964209; PubMed
763 Central PMCID: PMC10712736.
- 764 7. Goto N, Westcott PMK, Goto S, Imada S, Taylor MS, Eng G, et al. SOX17 enables
765 immune evasion of early colorectal adenomas and cancers. *Nature*. 2024;627(8004):636-45.
766 Epub 20240228. doi: 10.1038/s41586-024-07135-3. PubMed PMID: 38418875.
- 767 8. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, et al.
768 Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant
769 tumor progression. *Cancer Cell*. 2011;19(1):72-85. doi: 10.1016/j.ccr.2010.11.011. PubMed
770 PMID: 21251614; PubMed Central PMCID: PMC3069809.
- 771 9. Kaukonen R, Mai A, Georgiadou M, Saari M, De Franceschi N, Betz T, et al. Normal
772 stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-
773 mediated transcription. *Nat Commun*. 2016;7:12237. Epub 20160804. doi:
774 10.1038/ncomms12237. PubMed PMID: 27488962; PubMed Central PMCID: PMC4976218.
- 775 10. Brugger MD, Valenta T, Fazilaty H, Hausmann G, Basler K. Distinct populations of crypt-
776 associated fibroblasts act as signaling hubs to control colon homeostasis. *PLoS Biol*.
777 2020;18(12):e3001032. Epub 20201211. doi: 10.1371/journal.pbio.3001032. PubMed PMID:
778 33306673; PubMed Central PMCID: PMC7758045.
- 779 11. Cukierman E. A Reflection on How Carcinoma-Associated Fibroblasts Were Recognized
780 as Active Participants of Epithelial Tumorigenesis. *Cancer Res*. 2021;81(18):4668-70. doi:
781 10.1158/0008-5472.CAN-21-2553. PubMed PMID: 34526348.
- 782 12. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in
783 cancer. *Nat Rev Cancer*. 2004;4(11):839-49. doi: 10.1038/nrc1477. PubMed PMID: 15516957.
- 784 13. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis.
785 *Nat Med*. 2013;19(11):1423-37. doi: 10.1038/nm.3394. PubMed PMID: 24202395; PubMed
786 Central PMCID: PMC3954707.
- 787 14. Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic
788 Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. *Cell Stem Cell*.
789 2019;24(1):65-78. Epub 20181213. doi: 10.1016/j.stem.2018.11.011. PubMed PMID: 30554963;
790 PubMed Central PMCID: PMC7297507.
- 791 15. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al.
792 Reconstruction of functionally normal and malignant human breast tissues in mice. *Proc Natl*
793 *Acad Sci U S A*. 2004;101(14):4966-71. Epub 20040329. doi: 10.1073/pnas.0401064101.
794 PubMed PMID: 15051869; PubMed Central PMCID: PMC387357.
- 795 16. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ
796 to invasive breast carcinoma transition. *Cancer Cell*. 2008;13(5):394-406. doi:
797 10.1016/j.ccr.2008.03.007. PubMed PMID: 18455123; PubMed Central PMCID: PMC3705908.
- 798 17. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. *Annu Rev*
799 *Pathol*. 2006;1:119-50. doi: 10.1146/annurev.pathol.1.110304.100224. PubMed PMID:
800 18039110.
- 801 18. Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, et al. Lung adenocarcinoma
802 promotion by air pollutants. *Nature*. 2023;616(7955):159-67. Epub 20230405. doi:

- 803 10.1038/s41586-023-05874-3. PubMed PMID: 37020004; PubMed Central PMCID:
804 PMC7614604.
- 805 19. Braxton AM, Kiemen AL, Grahn MP, Forjaz A, Parksong J, Mahesh Babu J, et al. 3D
806 genomic mapping reveals multifocality of human pancreatic precancers. *Nature*.
807 2024;629(8012):679-87. Epub 20240501. doi: 10.1038/s41586-024-07359-3. PubMed PMID:
808 38693266.
- 809 20. Carpenter ES, Elhossiny AM, Kadiyala P, Li J, McGue J, Griffith BD, et al. Analysis of
810 Donor Pancreata Defines the Transcriptomic Signature and Microenvironment of Early
811 Neoplastic Lesions. *Cancer Discov*. 2023;13(6):1324-45. doi: 10.1158/2159-8290.CD-23-0013.
812 PubMed PMID: 37021392; PubMed Central PMCID: PMC10236159.
- 813 21. Helms EJ, Berry MW, Chaw RC, DuFort CC, Sun D, Onate MK, et al. Mesenchymal
814 Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated
815 Fibroblasts. *Cancer Discov*. 2022;12(2):484-501. Epub 20210921. doi: 10.1158/2159-8290.CD-
816 21-0601. PubMed PMID: 34548310; PubMed Central PMCID: PMC8831457.
- 817 22. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells
818 maintain haematopoietic stem cells. *Nature*. 2012;481(7382):457-62. Epub 20120125. doi:
819 10.1038/nature10783. PubMed PMID: 22281595; PubMed Central PMCID: PMC3270376.
- 820 23. Haberman ER, Sarker G, Arus BA, Ziegler KA, Meunier S, Martinez-Sanchez N, et al.
821 Immunomodulatory leptin receptor(+) sympathetic perineurial barrier cells protect against
822 obesity by facilitating brown adipose tissue thermogenesis. *Immunity*. 2024;57(1):141-52 e5.
823 Epub 20231212. doi: 10.1016/j.immuni.2023.11.006. PubMed PMID: 38091996.
- 824 24. Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing
825 reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its
826 aetiology. *Nat Commun*. 2013;4:2823. doi: 10.1038/ncomms3823. PubMed PMID: 24264436;
827 PubMed Central PMCID: PMC4059406.
- 828 25. Buechler MB, Pradhan RN, Krishnamurty AT, Cox C, Calviello AK, Wang AW, et al.
829 Cross-tissue organization of the fibroblast lineage. *Nature*. 2021;593(7860):575-9. Epub
830 20210512. doi: 10.1038/s41586-021-03549-5. PubMed PMID: 33981032.
- 831 26. Donahue KL, Watkoske HR, Kadiyala P, Du W, Brown K, Scales MK, et al. Oncogenic
832 KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote
833 tumor growth. *Cancer Discov*. 2024. Epub 20240703. doi: 10.1158/2159-8290.CD-24-0100.
834 PubMed PMID: 38958646.
- 835 27. Lee Y, Leslie J, Yang Y, Ding L. Hepatic stellate and endothelial cells maintain
836 hematopoietic stem cells in the developing liver. *J Exp Med*. 2021;218(3). doi:
837 10.1084/jem.20200882. PubMed PMID: 33151261; PubMed Central PMCID: PMC7649724.
- 838 28. Auciello FR, Bulusu V, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, et al. A Stromal
839 Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression. *Cancer Discov*.
840 2019;9(5):617-27. Epub 20190305. doi: 10.1158/2159-8290.CD-18-1212. PubMed PMID:
841 30837243; PubMed Central PMCID: PMC6497553.
- 842 29. Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, et al. Deep
843 Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. *Cell*.
844 2018;174(4):968-81 e15. Epub 20180802. doi: 10.1016/j.cell.2018.07.010. PubMed PMID:
845 30078711; PubMed Central PMCID: PMC6086938.
- 846 30. Zhou BO, Yu H, Yue R, Zhao Z, Rios JJ, Naveiras O, et al. Bone marrow adipocytes
847 promote the regeneration of stem cells and haematopoiesis by secreting SCF. *Nat Cell Biol*.
848 2017;19(8):891-903. Epub 20170717. doi: 10.1038/ncb3570. PubMed PMID: 28714970;
849 PubMed Central PMCID: PMC5536858.
- 850 31. Lee HJ, Lee J, Yang MJ, Kim YC, Hong SP, Kim JM, et al. Endothelial cell-derived stem
851 cell factor promotes lipid accumulation through c-Kit-mediated increase of lipogenic enzymes in
852 brown adipocytes. *Nat Commun*. 2023;14(1):2754. Epub 20230513. doi: 10.1038/s41467-023-
853 38433-5. PubMed PMID: 37179330; PubMed Central PMCID: PMC10183046.

- 854 32. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, et al. Integrated
855 analysis of multimodal single-cell data. *Cell*. 2021;184(13):3573-87 e29. Epub 20210531. doi:
856 10.1016/j.cell.2021.04.048. PubMed PMID: 34062119; PubMed Central PMCID: PMC8238499.
- 857 33. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, 3rd, et al.
858 Comprehensive Integration of Single-Cell Data. *Cell*. 2019;177(7):1888-902 e21. Epub
859 20190606. doi: 10.1016/j.cell.2019.05.031. PubMed PMID: 31178118; PubMed Central PMCID:
860 PMC6687398.
- 861 34. Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell
862 transcriptional landscape of mammalian organogenesis. *Nature*. 2019;566(7745):496-502. Epub
863 20190220. doi: 10.1038/s41586-019-0969-x. PubMed PMID: 30787437; PubMed Central
864 PMCID: PMC6434952.
- 865 35. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and
866 accurate integration of single-cell data with Harmony. *Nat Methods*. 2019;16(12):1289-96. Epub
867 20191118. doi: 10.1038/s41592-019-0619-0. PubMed PMID: 31740819; PubMed Central
868 PMCID: PMC6884693.
- 869 36. Apte MV, Haber PS, Applegate TL, Norton ID, McCaughan GW, Korsten MA, et al.
870 Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. *Gut*.
871 1998;43(1):128-33. doi: 10.1136/gut.43.1.128. PubMed PMID: 9771417; PubMed Central
872 PMCID: PMC1727174.
- 873 37. Zhao L, Cai B, Lu Z, Tian L, Guo S, Wu P, et al. Modified methods for isolation of
874 pancreatic stellate cells from human and rodent pancreas. *J Biomed Res*. 2016;30(6):510-6.
875 Epub 20160615. doi: 10.7555/JBR.30.20160033. PubMed PMID: 27924070; PubMed Central
876 PMCID: PMC5138584.
- 877 38. Galaxy C. The Galaxy platform for accessible, reproducible and collaborative biomedical
878 analyses: 2022 update. *Nucleic Acids Res*. 2022;50(W1):W345-W51. doi: 10.1093/nar/gkac247.
879 PubMed PMID: 35446428; PubMed Central PMCID: PMC9252830.
- 880 39. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and
881 collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics*. 2013;14:128. Epub
882 20130415. doi: 10.1186/1471-2105-14-128. PubMed PMID: 23586463; PubMed Central
883 PMCID: PMC3637064.
- 884 40. Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online
885 platform for data visualization and graphing. *PLoS One*. 2023;18(11):e0294236. Epub
886 20231109. doi: 10.1371/journal.pone.0294236. PubMed PMID: 37943830; PubMed Central
887 PMCID: PMC10635526.

888

889 **Figure legends**

890

891 **Figure 1: Pancreatic stellate cells contribute to the stromal microenvironment throughout** 892 **tumorigenesis**

893 **A**, Genetic schema of *Kras*^{FSF-G12D/+}; *Trp53*^{FRT/+}; *Pdx1-FlpO*; *Rosa26*^{mTmG/+}; *Fabp4-Cre* murine
894 model. **B**, Representative images of IHC staining for GFP (green) and Podoplanin (PDPN,
895 magenta) among normal pancreas, PanIN lesions, and mPDAC lesions. Scale bar, 10 μ m. **C**, IHC
896 staining quantification of percent GFP⁺PDPN⁺ (double-positive) cells over total PDPN⁺ expression
897 among the 3 disease states in **B** (n = 3). **D**, Representative images of IHC staining for GFP (green)
898 and CD31 (magenta) within normal pancreas (n = 5). Scale bar, 10 μ m. **E**, Representative images

899 of IHC staining for GFP (green) and CD31 (magenta) within GEMM pancreata (n = 3). Scale bar,
900 20 μ m. **F**, Representative images of IHC staining for GFP (green) and CD31 (magenta) within
901 pancreata of KPC-derived orthotopically implanted PDAC in *Rosa26^{mTmG/+};Fabp4-Cre* mice (n =
902 3). Scale bar, 10 μ m.

903

904 **Figure 2: Mesenchymal KITL loss within PSCs accompanies pancreatic tumorigenesis**

905 **A**, UMAP visualization of *Vim*, *Pi16*, and *Col15a1* gene expression in normal pancreatic stellate
906 cells (PSCs) and PSC-derived cancer associated fibroblasts scRNA-seq dataset (n = 2 replicates
907 pooled from n = 5 mice per arm). **B**, UMAP visualization of *Il6*, *Il33*, and *Col1a2* gene expression
908 from normal pancreatic stellate cells (PSCs) and PSC-derived cancer associated fibroblasts
909 scRNA-seq dataset (n = 2 replicates pooled from n = 5 mice per arm). **C**, UMAP visualization of
910 *Kitl* transcript expression in normal pancreatic stellate cells (PSCs) and PSC-derived cancer
911 associated fibroblasts scRNA-seq dataset (n = 2 replicates pooled from n = 5 mice per arm). **D**,
912 Left: qRT-PCR analysis of *Kitl* in quiescent (Day 0) and activated (Day 7) primary pancreatic
913 stellate cells (PSCs). Right: Quantikine ELISA KITL measurement of supernatant collected from
914 primary PSCs in pre-activated (Day 2) and activated state (Day 10) after 48 hours incubation with
915 media change on Day 8 to harvest for Day 10 sample. Immortalized ImpSC-1 included as
916 reference point. Data represents biological triplicate plotted as mean \pm SEM. Significance was
917 determined by ordinary one-way ANOVA; ns = not significant, *P \leq 0.05, **P \leq 0.01. **E**,
918 Representative images of RNA FISH staining for *Fabp4* (green) and *Kitl* (red) in murine normal
919 pancreas (n = 3). Scale bar, 10 μ m. Below, representative RNAScope staining of GFP (green)
920 protein and *Kitl* (red) mRNA in PDAC from the GEMM depicted in **1A** (n = 3). Scale bar, 10 μ m.
921 **F**, Representative images of RNA FISH staining for *VIM* (green) and *KITL* (red) in human PDAC
922 tissues between benign adjacent and PDAC regions (n = 3). Scale bar, 10 μ m. **G**, Representative
923 images of RNAScope staining for *Kitl* (red) mRNA expression, GFP (green) and CD31 (magenta)
924 in murine normal pancreas from *Rosa26^{mTmG/+};Fabp4-Cre* mice (n = 3). Scale bar, 20 μ m. **H**,
925 Representative images of RNAScope staining for GFP (green) protein and *Kitl* (red) mRNA in
926 GEMM low-grade PanIN (n = 3). Scale bar, 20 μ m.

927

928 **Figure 3: KITL regulates PSC state and pancreas tissue homeostasis**

929 **A**, Volcano plot of all upregulated, non-significant, and downregulated differentially expressed
930 genes (DEGs) as defined by the Wald test (p.adj <0.05 and log₂FC >1) from *Kitl* overexpression
931 (*Kitl* OE) ImpSC-1 bulk-RNA seq dataset with representative gene labels included. Data represent
932 3 biological repeats. **B**, Gene ontology (GO) analysis of upregulated and downregulated genes in

933 immortalized pancreatic stellate cells (ImPSC-1) overexpressing *Kitl*. Top 10 enrichment
934 categories ranked by adjusted p-values plotted in each direction. **C**, Representative images of
935 CODEX staining (left) and quantification (right) for GFP (green) and CD31 (red) in normal
936 pancreas from *Fabp4-Cre* or *Kitl^{fl/fl};Fabp4-Cre* mouse model (n= 2 mice per arm). Scale Bar: 100
937 μ m. Data are represented as mean \pm SD. **D**, Representative images of CODEX composite
938 staining (left) and quantification (right) for CD45 (white) in normal pancreas from *Fabp4-Cre* or
939 *Kitl^{fl/fl};Fabp4-Cre* mouse model (n= 2 mice per arm). Scale Bar: 50 μ m. Data are represented as
940 mean \pm SD. **E**, Representative images of IHC staining for GFP (green), cKIT receptor (KIT, red),
941 and VIM (magenta) in healthy murine pancreas from *Rosa26^{mTmG/+};Fabp4-Cre* mice. Scale bar,
942 10 μ m. **F**, Representative images of IHC staining for CD31 (green) and cKit receptor (KIT, red) in
943 healthy murine pancreas. Scale bar, 10 μ m. **G**, Representative images of IHC staining for panCK
944 (white) and cKit receptor (KIT, red) in healthy murine pancreas. Scale bar, 10 μ m. **H**,
945 Representative H&E images between caerulein-treated *Fabp4-Cre* and *Kitl^{fl/fl};Fabp4-Cre* mice.
946 Scale bar, 100 μ m. **I**, Representative images of IHC staining (left) for panCK (green) and Amylase
947 (red) between caerulein-treated *Fabp4-Cre* and *Kitl^{fl/fl};Fabp4-Cre* mice. Scale bar, 10 μ m. PanCK
948 quantification on right (n = 3 mice per arm). For comparisons between two groups, Student's two-
949 tailed t-test was used. Data are represented as mean \pm SEM. *P < 0.05.

950

951 **Figure 4: Mesenchymal KITL restrains pancreatic tumor growth**

952 **A**, Average tumor area (mm^2) between *Fabp4-Cre* control and *Kitl^{fl/fl};Fabp4-Cre* mice, injected
953 with KPC-derived murine PDAC cells 6419c5 (n = 7 mice per arm). Data are represented as mean
954 \pm SEM. Slopes tabulated via simple linear regression analysis. **B**, Tumor weights (g) at
955 experimental endpoint between *Fabp4-Cre* control and *Kitl^{fl/fl};Fabp4-Cre* mice, injected with KPC-
956 derived murine PDAC cells 6419c5 (n = 7 mice per arm). Data are represented as mean \pm SEM.
957 **C**, Representative H&E images of *Fabp4-Cre* control and *Kitl^{fl/fl};Fabp4-Cre* mice injected with
958 KPC-derived murine PDAC cells 6419c5, at the same experimental endpoint. Scale bar, 1mm. **D**,
959 Kaplan–Meier plot depicting percent probability of survival between *Fabp4-Cre* control and
960 *Kitl^{fl/fl};Fabp4-Cre* mice, injected with KPC-derived murine PDAC cells 6419c5 (n = 7 mice per
961 arm). Log-rank p value = 0.0072. **E**, Representative images of IHC staining (bottom) and
962 quantification (top) of α SMA and podoplanin (PDPN) between *Fabp4-Cre* control mice and
963 *Kitl^{fl/fl};Fabp4-Cre* mice, injected with KPC-derived murine PDAC cells 6419c5 (n = 3 mice per
964 arm). Data are represented as mean \pm SEM. *, P < 0.0332; **, P < 0.0021; ***, P < 0.0002; ****,
965 P < 0.0001 Mann-Whitney unpaired t test; ns, not significant.

966

967 **Supplementary Figure S1: scRNA-seq reveals gene expression programs in PSCs and**
968 **PSC-derived CAFs**

969 **A**, UMAP (uniform manifold approximation and projection) visualization of *Cspg4* and *Rgs5* gene
970 expression in scRNA-seq dataset of pancreatic stellate cells (PSCs) and PSC-derived cancer
971 associated fibroblasts (CAFs) isolated from healthy pancreas and orthotopic tumors respectively.
972 **B**, UMAP (uniform manifold approximation and projection) visualization of *Csf1r* and *Adgre1* gene
973 expression in pancreatic stellate cells (PSCs) and PSC-derived cancer associated fibroblasts
974 scRNA-seq dataset (n = 2 replicates pooled from n = 5 mice per arm). **C**, Representative images
975 of IHC staining for GFP (green) and CD68 (red) in normal pancreas tissue from
976 *Rosa26^{mTmG/+};Fabp4-Cre* mice (n = 3 mice). Scale bar: 50 μ m.

977

978 **Supplementary Figure S2: *Kitl* is expressed by healthy pancreatic mesenchyme and**
979 **reduced upon activation to a CAF phenotype**

980 **A**, (Left) UMAP illustrating the cellular landscape of normal pancreatic (blue) and PDAC (red)
981 mesenchymal cells, comprising 5,337 normal and 2,861 tumor cells. Harmony was used to
982 integrate the datasets and correct for batch effects. (Right) Monocle 3 trajectory analysis was
983 used to depict expression of the *Kitl* gene along the inferred pseudotime trajectory. Cells are
984 colored based on *Kitl* expression levels, with values ranging from low (black) to high (yellow),
985 revealing the spatial and temporal expression patterns of *Kitl* (n = 2 replicates pooled from n = 5
986 mice per arm). **B**, UMAP (uniform manifold approximation and projection) visualization of *Lepr*
987 gene expression in normal pancreatic stellate cells (PSCs) and PSC-derived cancer associated
988 fibroblasts scRNA-seq dataset (n = 2 replicates pooled from n = 5 mice per arm). **C**, qRT-PCR of
989 *Lepr ObRa* and *Lepr ObRb* isoforms in primary pancreatic stellate cells harvested at indicated
990 time point. FC1245 PDAC cell line was included as a reference point. Data represents biological
991 triplicates plotted as mean \pm SEM. Significance was determined by ordinary one-way ANOVA; ns
992 = not significant, *P \leq 0.05, **P \leq 0.01. **D**, Left: qRT-PCR analysis of *Acta2* in quiescent (Day 0)
993 and activated (Day 7) primary pancreatic stellate cells (PSCs) with immortalized ImPSC-1
994 included as reference point. Data represents biological triplicate plotted as mean \pm SEM.
995 Significance was determined by ordinary one-way ANOVA; ns = not significant, ****P \leq 0.0001.
996 Right: Representative immunofluorescence staining for α -SMA and Nile Red staining in primary
997 pancreatic stellate cells fixed at indicated time point (n= 3 biological replicates). Scale Bar: 100
998 μ m. **E**, Representative images of RNA FISH staining for *Fabp4* (green) and *Kitl* (red) in murine
999 normal pancreas between *Fabp4-Cre* control and *Kitl^{fl/fl};Fabp4-Cre* mice. Scale bar, 10 μ m.

1000

1001 **Supplementary Figure S3: Stromal KITL promotes regulation of pancreas tissue**
1002 **architecture**

1003 **A**, Soluble *Kitl* transcript level (left) and protein secretion (right), quantitated using qRT-PCR and
1004 ELISA respectively, of immortalized pancreatic stellate cells (ImpSC-1) expressing stable *Kitl*
1005 knockdown (*shKitl*) or overexpression (*Kitl* OE). Parental ImpSC-1 serves as control for both
1006 stable cell lines. Data represents biological triplicates plotted as mean \pm SEM. Significance was
1007 determined by ordinary one-way ANOVA; ns = not significant, * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$.
1008 **B**, qRT-PCR of *cKit* in quiescent (Day 0) and activated (Day 7) primary pancreatic stellate cells
1009 (PSCs) with immortalized ImpSC-1 included as reference point. Data represents biological
1010 triplicate plotted as mean \pm SEM. Significance was determined by ordinary one-way ANOVA; ns
1011 = not significant, * $P \leq 0.05$. **C**, Volcano plot of all upregulated, non-significant, and downregulated
1012 differentially expressed genes as defined by the Wald test ($p_{adj} < 0.05$ and $\log_2FC > 1$) from *Kitl*
1013 knock down (*shKitl*) ImpSC-1 bulk-RNA seq dataset with representative gene labels included.
1014 Data is representative of 3 biological repeats. **D**, Gene ontology (GO) analysis of upregulated and
1015 downregulated differentially expressed genes in immortalized pancreatic stellate cells (ImpSC-1)
1016 with *Kitl* stable knockdown. Top 10 enrichment categories ranked by adjusted p-values plotted in
1017 each direction.


1018

1019 **Supplementary Figure S4: Stromal KITL promotes pancreas tissue homeostasis**


1020 **A**, CODEX quantification of Vimentin (VIM) between healthy pancreata of *Fabp4-Cre* control and
1021 *Kitl^{fl/fl};Fabp4-Cre* mice (n = 2 mice per arm). Data are represented as as mean \pm SD. **B**, IHC
1022 quantification of CD31⁺ area between healthy pancreata of *Fabp4-Cre* control and *Kitl^{fl/fl};Fabp4-*
1023 *Cre* mice (n = 5 for control; n = 4 for *Kitl^{fl/fl};Fabp4-Cre*). Data are represented as mean \pm SEM. **C**,
1024 Representative images of CODEX staining (left) and quantification (right) of α SMA and Vimentin
1025 (VIM) between healthy pancreata of *Fabp4-Cre* control and *Kitl^{fl/fl};Fabp4-Cre* mice. CODEX
1026 quantification (right) of VIM expression (n = 2 mice per arm). Data are represented as as mean \pm
1027 SD. **D**, Flow cytometry analysis of cKIT receptor, EpCAM, and CD45 in healthy pancreata of
1028 C57BL/6J age-matched male mice (n = 5). **E**, Flow cytometry analysis of cKIT receptor, EpCAM,
1029 and CD31 in healthy pancreata of C57BL/6J age-matched male mice (n = 5). *, $P < 0.0332$; **, P
1030 < 0.0021 ; ***, $P < 0.0002$; ****, $P < 0.0001$ Mann-Whitney unpaired t test; ns, not significant.

Figure 1


A




B




C



D



E



F




Figure 2




Figure 3






Figure 4




Supplementary Figure 1




Supplementary Figure 2


A




B




C




D



E



Supplementary Figure 3



Supplementary Figure S4

